Details for Patent: 6,391,874

✉ Email this page to a colleague

Summary for Patent: 6,391,874

Patent landscape, scope, and claims:

Title:	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
Abstract:	Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH.sub.2), (CH.sub.2)W, or W, in which W is O, S(O).sub.m wherein m is 0, 1 or 2, or NR.sup.a wherein R.sup.a is hydrogen or a C.sub.1-8 alkyl group; R.sup.1 represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O).sub.m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O).sub.m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R.sup.1 being optionally substituted by one or more R.sup.3 ;groups; P=0 to 3; U, R.sup.2, R.sup.3 are as defined in the application. ##STR1##
Inventor(s):	Cockerill; George Stuart (Herts, GB), Carter; Malcolm Clive (Herts, GB), Guntrip; Stephen Barry (Herts, GB), Smith; Kathryn Jane (Herts, GB)
Assignee:	SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:	09/214,267
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Dosage form; Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 6,391,874

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 6,391,874

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9614755	Jul 13, 1996
United Kingdom	9625458	Dec 07, 1996

PCT Information
PCT Filed	July 11, 1997	PCT Application Number:	PCT/EP97/03672
PCT Publication Date:	January 22, 1998	PCT Publication Number:	WO98/02434

International Family Members for US Patent 6,391,874

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	007857	⤷ Subscribe
Austria	227283	⤷ Subscribe
Australia	3766897	⤷ Subscribe
Cyprus	2451	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.